Longevity & AgingVideo Summary

Why Bad Data Is Slowing Longevity Research More Than Lack of Funding

A UCSF researcher reveals that data access and reproducibility failures may be longevity science's biggest hidden bottleneck.

Friday, June 26, 2026 4 views
Published in Sheekey Science Show
YouTube thumbnail: Why Bad Data Is Slowing Longevity Research More Than Lack of Funding

Summary

Longevity researchers say lack of data access is a bigger problem than funding shortages — and only 30–50% of biological studies can be reproduced. Dr. Timofey Glinin, a postdoc at UCSF with over a decade in aging research, discusses how poor data sharing practices are costing the field years of potential breakthroughs. He co-founded First Approval, a platform designed to make raw biological datasets publishable and citable. He also helped build the Open Genes database, cataloguing over 2,400 aging-related genes. The conversation covers the reproducibility crisis in biology, why raw data matters more than processed results, and how open data infrastructure could accelerate discoveries in aging science.

Detailed Summary

The longevity research field faces a hidden infrastructure crisis that may be slowing progress more than any funding gap. According to Dr. Timofey Glinin, a postdoctoral researcher at UCSF and co-founder of the data-sharing platform First Approval, surveys of longevity scientists consistently rank lack of data access as their top barrier — above regulatory hurdles and financial constraints. This finding challenges the common assumption that money is the primary bottleneck in aging research.

The reproducibility crisis sits at the heart of the problem. Only 30–50% of biological studies can be independently reproduced, meaning a significant portion of published research may be building on flawed or unverifiable foundations. When raw datasets are not shared alongside published papers, other researchers cannot check, extend, or build upon findings — wasting enormous amounts of time and resources across the field.

Glinin draws an important distinction between raw and processed data. Processed data — the charts and statistics in a published paper — strips out the granular information other scientists need to re-analyze or repurpose findings. Raw datasets preserve that detail and enable entirely new questions to be asked from existing experiments. Yet most journals have no mechanism to publish or incentivize raw data sharing.

First Approval is designed to fill this gap by creating a dedicated platform where biological datasets can be published, peer-reviewed, and cited independently of traditional journal articles. The platform is also running a student competition with $7,500 in prizes to reward excellent dataset submissions, aiming to build a culture of data openness from early career stages.

For longevity-focused readers, the implication is significant: the pace of anti-aging discoveries depends not just on new experiments but on how efficiently the scientific community can learn from existing ones. Better data infrastructure could meaningfully compress the timeline to actionable longevity interventions.

Key Findings

  • Longevity researchers rank data access as a bigger barrier than funding or regulation.
  • Only 30–50% of biological studies are reproducible, undermining research reliability.
  • Raw data sharing — not just published results — is critical for scientific progress.
  • First Approval platform allows raw biological datasets to be published and cited independently.
  • Open Genes database catalogs 2,400+ aging-related genes as a model for open data in longevity.

Methodology

This is a long-form interview on the Sheekey Science Show, hosted by Eleanor Sheekey, a science communicator with an academic background. The guest holds a postdoctoral position at UCSF with over 10 years in aging research. The channel regularly features credible researchers in longevity and biology.

Study Limitations

This summary is based on the video description only — no transcript was available, so specific claims, data sources, and nuances from the spoken conversation could not be verified. Statistics cited (e.g., 30–50% reproducibility) should be cross-referenced with primary literature. The guest has a direct commercial interest in First Approval, which may introduce promotional framing.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: